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A B S T R A C T   
Hypophosphatasia (HPP) is a rare disorder resulting from biallelic loss-of-function variants or monoallelic 
dominant negative variants in the ALPL gene. We herein describe the clinical outcome of a 32-year-old woman 
with childhood-onset HPP caused by compound heterozygous variants in ALPL. Her chief complaints were severe 
musculoskeletal pain, muscle weakness, and impaired daily activities necessitating assistance in housework and 
child-rearing in addition to a history of early tooth loss and mildly short stature. Asfotase alfa therapy produced a 
remarkable increase in muscle strength and daily activities and markedly reduced musculoskeletal pain. Drug 
efficacy was clearly demonstrated through multiple test batteries (muscle strength test using microFET®2, six- 
minute walking test, Stair Climb Test, rising-from-floor-time test, and number-of-steps test using Actigraph®) 
currently adopted as standardized evaluations in Duchenne muscular dystrophy clinical trials since no test 
batteries for HPP have been established to date. These tests may also be promising for the assessment of HPP.   
1. Introduction 
Hypophosphatasia (HPP) is a rare disorder caused by biallelic loss- 
of-function variants or monoallelic dominant negative variants in the 
ALPL gene encoding tissue non-specific alkaline phosphatase (TNSALP) 
[1]. HPP is classified into perinatal lethal, prenatal benign, infantile, 
childhood, adult, and odontohypophosphatasia forms [2]. Asfotase alfa 
is a human recombinant TNSALP enzyme replacement agent approved 
for patients with pediatric-onset HPP [3]. 
An open-label study of infants and young children with severe 
HPP found that treatment with asfotase alfa for up to 7 years 
improved HPP-related skeletal abnormalities [4]. Asfotase alfa for 
infantile and childhood HPP was also shown to ameliorate motor 
function and height gains [5]. To date, however, there are no data on 
the efficacy of asfotase alfa in adult patients with childhood-onset 
HPP exhibiting musculoskeletal complications and impaired daily 
activities. 
We herein describe the clinical outcome of a woman with HPP who 
had experienced the loss of her deciduous teeth in early childhood and 
displayed severe musculoskeletal pain, muscle weakness, and decreased 
daily activities. Successful treatment with asfotase alfa was clearly de-
monstrated using multiple detailed test batteries for motor function, 
https://doi.org/10.1016/j.ymgmr.2020.100643 
Received 30 July 2020; Received in revised form 21 August 2020; Accepted 21 August 2020    
⁎ Correspondence to: H. Nishizawa, Faculty of Health Sciences, Department of Medicine, Shinshu University, 3-1-1 Asahi, Matsumoto 390-8621, Nagano, Japan. 
⁎⁎ Correspondence to: T. Kosho, Department of Medical Genetics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Nagano, Japan. 
E-mail addresses: hitnishi@shinshu-u.ac.jp (H. Nishizawa), ktomoki@shinshu-u.ac.jp (T. Kosho). 
Molecular Genetics and Metabolism Reports 25 (2020) 100643
Available online 09 September 2020
2214-4269/ © 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
T
pain, and activities of daily living (ADL) currently adopted in clinical 
trials of Duchenne muscular dystrophy (DMD). 
2. Material and method 
2.1. Subject 
The patient was a 32-year-old woman born to non-consanguineous 
Japanese parents. At one year of age, she began losing her deciduous 
teeth, which had erupted from the age of 7 months. A concomitant 
serum ALP level of under 10 IU/L (normal range: 395–1289 IU/L ac-
cording to Japan Society of Clinical Chemistry [JSCC] consensus) re-
sulted in the diagnosis of HPP. She showed mild growth restriction 
during childhood; her height was 75.5 cm (−1.7 standard deviation 
[SD]) at 19 months of age and 86.2 cm (−1.9 SD) at the age of 3 years 
and 1 month. She lost her adult teeth during college and experienced 
significant restrictions in ADL due to severe musculoskeletal pain and 
generalized fatigue. Genetic testing revealed compound heterozygous 
pathogenic variants in ALPL, namely c.[572A > G];[1276G > A], p. 
[Glu191Gly];[Gly426Ser]. 
Upon presentation at our department at the age of 31 years, her 
height was 147 cm (−2.0 SD) and weight was 39 kg (−2.5 SD). She 
complained of severe headaches and neck pain that caused nausea and 
had generalized musculoskeletal pain leading to difficulties in house-
work and child-rearing. Her serum ALP level was 6 IU/L (normal range: 
106–322 IU/L according to JSCC consensus). She commenced asfotase 
alpha (Strensiq®) therapy at 6 mg/kg/week subcutaneously, which 
produced remarkable decreases in plasma pyridoxal 5′-phosphate (PLP) 
and PLP/pyridoxal ratio from 145.4 nmol/L and 27.8 to 8.4 nmol/L and 
0.5, respectively [6]. Dual-energy X-ray absorptiometry showed a mild 
increase in bone mineral density from 1.001 g/cm2 at the lumbar 1–4 
region (L1–4) (Z-score: −1.0) and 0.615 g/cm2 at the right total hip (Z- 
score: −2.5) before treatment to 1.042 g/cm2 at L1–4 (Z-score: −0.8) 
and 0.651 g/cm2 at the right total hip (Z-score: −2.3) after 7 months of 
therapy. A high-precision body component analyzer (InBody770®; In-
Body Japan, Tokyo, Japan) revealed slightly increased skeletal muscle 
mass from 14.8 kg before treatment to 15.2 kg after 12 months of 
therapy (normal range: 16.8–20.6 kg). 
2.2. Motor function measurements 
Motor function was measured using the following five test batteries, 
which have been adopted in DMD clinical trials [7]. MicroFET®2 
(Hoggan Scientific, LLC, Salt Lake City, USA) was used to measure 
abduction strength of the hip joints, flexion and extension of the knee 
joints, flexion of the shoulder joints, and flexion and extension of the 
elbow joints. The six-minute walking test (6MWT), Stair Climb Test, 
and rising-from-floor-time test were employed to measure overall 
motor function. The number-of-steps test via Actigraph® (MTN-220, 
ESTERA, Saitama, Japan) was used to evaluate the total amount of 
physical activity. All measurements were performed by an experienced 
physiotherapist (HN) engaged in clinical trials of DMD. Additionally, a 
visual analog scale (VAS) was used to obtain total pain values and lo-
cations of the most severe pain in her daily life. This study was ap-
proved by the Ethics Committee of Shinshu University School of Med-
icine (#4654). Written consent was obtained from the patient. 
3. Results 
MicroFET®2 analysis revealed gradually increased strength in all 
muscles investigated (Fig. 1A, B). The 6MWT showed a marked increase 
in distance from 460 m before treatment to 562 m after 12 months of 
therapy (Fig. 1C). Both Stair Climb Test (up and down) and rising-from- 
floor-time test scores were improved by the treatment (Fig. 1D). The 
average number of steps she could climb increased from 2591 to 4307 
(Fig. 1E). Her VAS score for pain was 9.5/10 before therapy, with 
multiple joints of the extremities affected and the most severe pain 
being in the neck. Although her pain score was drastically reduced to 
1.0 after 8 months of treatment (Fig. 1F), it increased to 5.4 at 
12 months of therapy due to greater daily activity from improved motor 
function and pain. 
4. Discussion 
This is the first report to present detailed data on improved motor 
function and relevant symptoms in an adult patient with childhood- 
onset HPP by asfotase alfa therapy. Drug efficacy was clearly demon-
strated using multiple test batteries already adopted in DMD clinical 
trials due to no established testing for motor function in HPP 
[8,9,10,11]. 
Instantaneous muscle strength as measured by microFET®2 showed 
marked enhancements in the upper (shoulders and elbows) and lower 
(hips and knees) limbs, which was consistent with the increased muscle 
mass detected by the InBody770®. The general strength and endurance 
of anti-gravity muscles as evaluated by the 6MWT, Stair Climb Test, and 
rising-from-floor-time test also revealed gains from the first month of 
therapy. Regarding total activities of daily life, Actigraph® showed an 
increase in the average number of steps from approximately four 
months of treatment. Pain levels estimated by VAS scores indicated 
marked relief until 8 months, with subsequent worsening that was at-
tributed to an increase in daily activity levels. Asfotase alfa therefore 
appeared to exert noticeable effects on instantaneous and endurable 
muscle strength. However, the precise mechanism remains unknown 
due to no available muscle histopathology or laboratory results. 
Moreover, her pain relief might have been associated with increased 
muscle strength in addition to other independent effects. 
The efficacy of 5-year asfotase alfa therapy on motor function was 
earlier demonstrated in 19 adolescent or adult patients with infantile or 
pediatric HPP. The 6MWT was used as a validated measure in combi-
nation with multiple exploratory tests, including the Bruininks- 
Oseretsky Test of Motor Proficiency (Running Speed and Agility subset 
and Strength subtest) for evaluating gross motor function, hand-held 
dynamometry for testing muscle strength of the hip extensors and ab-
ductors, the Lower Extremity Functional Scale to calculate the perfor-
mance of transitional movements, locomotion, climbing stairs, and 
squatting, and the Brief Pain Inventory-Short Form for assessing pain 
[12]. Phillips et al. also showed high test-retest reliability (r = 0.95; 
p  <  0.0001) for the 6MWT in HPP as well as sufficient validity (i.e., 
walking distance increased as the severity of skeletal disease decreased) 
[13]. 
Indicating the smallest benefit of value to the patient [14], the 
minimally clinically important difference (MCID) of the 6MWT is re-
portedly 31 m in adults with pediatric-onset HPP and 43 m in adoles-
cents with pediatric-onset HPP [13]. In the present case, the 6MWT 
distance surpassed both MCID values: 48 m at 3 months of treatment 
and 102 m at 12 months. 
5. Conclusion 
Asfotase alfa treatment was successful in an adult woman with 
childhood-onset HPP by markedly increasing muscle strength and daily 
activities while reducing musculoskeletal pain. Multiple test batteries, 
such as those adopted in DMD clinical trials, may also be useful to 
comprehensively evaluate motor function in HPP. 
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Fig. 1. Efficacy of asfotase alfa evaluated through multiple test batteries. 
Muscle strength measured by microFET®2 on (A) the right side and (B) the left side. Strength in various muscles showed consistent improvement. (C) Distances in the 
6-min walking test. Walking distance increased during 1–3 months and 9–12 months of treatment, with a plateau at 3–9 months. (D) Results of the Stair Climb Test 
and rising-from-floor-time test. 
The time for climbing up or down stairs and the time for standing from the floor decreased. 
(E) Number of steps measured by Actigraph®. Average and minimum step numbers increased after 4 months of treatment, while the maximum number of steps 
fluctuated. (F) VAS scores for whole-body pain. Pain scores reduced after 4 months of the treatment. However, pain increased after 12 months of therapy, presumably 
due to an increase in activities associated with improved pain and motor function. 
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